RIO DE JANEIRO, BRAZIL - The Brazilian Health Regulatory Agency (ANVISA) on Thursday, May 13, unanimously approved the use of two drugs, the monoclonal antibodies banlanivimab and etesevimab, for the treatment of coronavirus patients in the country.
The decision was announced during an extraordinary meeting and is of an emergency nature, with temporary authorization to meet the demands of the pandemic.
The associated antibodies are prescribed for adults and pediatric patients, over 12 years of age and weighing more than 40 kilos, with laboratory-proven infection and who are in the high-risk group for the disease (comorbidities, advanced age, obesity . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here